A decade-long deal sends part of NIH's infectious-disease budget to the Pentagon

NIH has signed a 10-year interagency agreement that routes part of the National Institute of Allergy and Infectious Diseases' budget to the Department of Defense. The deal funds Pentagon medical-countermeasure work on pandemic influenza, chemical, biological, radiological, and nuclear (CBRN) threats, and emerging infectious diseases, including some projects current NIH leadership had already declined to fund, at a moment when the civilian agency says it cannot issue the grants Congress has already given it.

The agreement, filed publicly by DoD on the Friday before the Labor Day weekend, locks in the transfer for ten years. Money flows from NIAID's FY2026 budget, $6.6 billion as allocated by Congress, to Defense, where it pays for staff and projects tied to DoD's medical-countermeasure mission. The document itself is filed as REDACTED, so the specific projects and dollar amounts within its scope are not publicly visible.

What is visible is the scale. According to Nature, DoD initially sought up to a third of NIAID's $6.6 billion FY2026 budget, roughly $2.2 billion, before being told to settle for closer to 10 percent, or about $660 million. Neither figure appears in the redacted agreement, and the final amount is not yet confirmed. The Ars Technica report walks through the timeline and the political reaction.

The transfer sits against two structural facts. The 2026 Defense budget, roughly $1 trillion, is under strain from the open-ended conflict with Iran. Medical-countermeasure work is one of the few lines that still has political and operational support across the Pentagon's civilian and combatant-command buyers. NIH, separately, is currently struggling to issue sufficient grants to use the money Congress has already allocated to it. NIAID's $6.6 billion is part of that larger unspent pool.

The second fact is where the political reaction has concentrated. If NIAID cannot deploy its own allocation, the administrative argument runs, moving a slice to DoD is a fiduciary reshuffle within the same statutory mission. CBRN and pandemic-influenza work already falls inside NIAID's mandate, and unspent congressional appropriations are at risk of being rescinded. The same arrangement also routes money to projects NIH leadership explicitly chose not to fund, and binds that choice for a decade.

House Democrats on the Appropriations Committee and Senator Patty Murray have publicly criticized the deal, framing it as a transfer of civilian health-research authority to the Pentagon. Science.org has covered the controversy as a case of NIH "caving" to Defense pressure. None of those characterizations appear in the agreement text. They are reactions to the leak and the filing.

The agreement text, what is visible of it, limits DoD's role to medical-countermeasure development and requires NIH involvement in project selection. It does not give DoD a veto over NIAID's broader portfolio, and it does not change NIAID's statutory mission. The mechanism is a budget transfer inside a defined scope, not a directive that reorients civilian public-health priorities.

If NIH cannot spend its congressional allocation, the dollars do not vanish; they get redirected, by whoever is positioned to receive them. A decade is long enough to shape a generation of basic and translational health research, especially in infectious disease, where NIAID has historically been the dominant US funder. Whether this transfer reads as a power shift or a fiduciary reshuffle depends on which projects DoD picks up, and whether NIH can, in practice, redirect the same dollars back into its own portfolio if grant issuance recovers.

The redacted agreement does not answer that question. The next concrete fact to watch is which NIH-rejected projects DoD actually funds, and whether the final transfer lands closer to the ~10 percent Nature reports as the working figure or the up-to-a-third DoD originally sought.